Eledon Pharmaceuticals, Inc. (ELDN)Â
NASDAQ$3.65
Market Cap
$218.05M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
74 of 924
Rank in Industry
53 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
ELDN Insider Trading Activity
ELDN Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $4,569,211 | 1 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| BVF PARTNERS L P/IL | 10 percent owner | 1 | $4.57M | 0 | $0 | $4.57M |
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Insider Activity of Eledon Pharmaceuticals, Inc.
Over the last 12 months, insiders at Eledon Pharmaceuticals, Inc. have bought $4.57M and sold $0 worth of Eledon Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Eledon Pharmaceuticals, Inc. have bought $2.33M and sold $2.57M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BVF PARTNERS L P/IL (10 percent owner) — $4.57M.
The last purchase of 1,927,937 shares for transaction amount of $4.57M was made by BVF PARTNERS L P/IL (10 percent owner) on 2024‑05‑09.
List of Insider Buy and Sell Transactions, Eledon Pharmaceuticals, Inc.
| 2024-05-09 | BVF PARTNERS L P/IL | 10 percent owner | 1.93M 7.8677% | $2.37 | $4.57M | +25.00% | ||
| 2023-05-05 | BVF PARTNERS L P/IL | 10 percent owner | 1.98M 11.9399% | $2.31 | $4.57M | -41.79% | ||
| 2022-11-23 | Perrin Steven | President | 1,000 0.0072% | $2.60 | $2,597 | -23.11% | ||
| 2021-12-20 | Gros David-Alexandre C | Chief Executive Officer | 2,000 0.0135% | $4.48 | $8,960 | -30.07% | ||
| 2021-08-17 | Gros David-Alexandre C | Chief Executive Officer | 4,000 0.0262% | $6.21 | $24,840 | -39.06% | ||
| 2021-06-11 | Little Paul Sean | CHIEF FINANCIAL OFFICER | 10,000 0.0681% | $8.87 | $88,700 | -46.53% | ||
| 2021-06-09 | Gros David-Alexandre C | Chief Executive Officer | 3,000 0.0203% | $8.01 | $24,030 | -40.88% | ||
| 2020-12-02 | Sale | OrbiMed Israel GP Ltd. | 10 percent owner | 103,200 6.5689% | $21.60 | $2.23M | -63.07% | |
| 2020-10-30 | Sale | Logos Global Management LP | 10 percent owner | 12,969 0.9094% | $26.64 | $345,559 | -62.38% | |
| 2020-10-30 | Logos Global Management LP | 10 percent owner | 92,040 6.1626% | $25.44 | $2.34M | -62.38% | ||
| 2019-05-21 | Sale | FLESHER GREGORY J. | Chief Executive Officer | 2,937 0.025% | $1.91 | $5,614 | -66.49% | |
| 2019-05-21 | Sale | TURKEL CATHERINE C. | President | 1,914 0.0163% | $1.91 | $3,658 | -66.49% | |
| 2019-05-21 | Sale | Kuwahara Jon | See Remarks | 1,058 0.009% | $1.91 | $2,022 | -66.49% | |
| 2019-05-20 | Sale | FLESHER GREGORY J. | Chief Executive Officer | 11,701 0.1045% | $1.96 | $22,953 | -65.78% | |
| 2019-05-20 | Sale | TURKEL CATHERINE C. | President | 7,623 0.068% | $1.96 | $14,953 | -65.78% | |
| 2019-05-20 | Sale | Kuwahara Jon | See Remarks | 4,218 0.0377% | $1.96 | $8,274 | -65.78% | |
| 2019-05-02 | OrbiMed Israel GP Ltd. | 646,204 6.2443% | $3.10 | $2M | -76.19% | |||
| 2019-05-02 | Chimovits Erez | director | 646,204 6.2443% | $3.10 | $2M | -76.19% | ||
| 2019-04-30 | Sale | LIFESCI INDEX PARTNERS LLC | 10 percent owner | 200 0.0017% | $2.70 | $540 | -75.47% | |
| 2018-09-12 | TURKEL CATHERINE C. | President | 16,632 0.1711% | $5.02 | $83,476 | -44.40% |
Total: 51
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| BVF PARTNERS L P/IL | 10 percent owner | 3361803 5.6275% | $12.27M | 2 | 0 | <0.0001% |
| Harrison Seth Loring | 7912079 13.2443% | $28.88M | 1 | 0 | ||
| Novartis Bioventures Ltd | 10 percent owner | 4493458 7.5218% | $16.4M | 1 | 9 | |
| Apple Tree Partners II - Annex, L.P. | 3568438 5.9734% | $13.02M | 1 | 0 | ||
| Chimovits Erez | director | 3183314 5.3287% | $11.62M | 1 | 0 | <0.0001% |
| Satter Muneer A | 10 percent owner | 1771688 2.9657% | $6.47M | 1 | 0 | |
| LIFESCI INDEX PARTNERS LLC | 10 percent owner | 1065867 1.7842% | $3.89M | 0 | 1 | |
| Logos Global Management LP | 10 percent owner | 224071 0.3751% | $817,859.15 | 1 | 1 | <0.0001% |
| FLESHER GREGORY J. | Chief Executive Officer | 156918 0.2627% | $572,750.70 | 1 | 2 | |
| TURKEL CATHERINE C. | President | 88662 0.1484% | $323,616.30 | 4 | 2 | <0.0001% |
| OrbiMed Israel GP Ltd. | 10 percent owner | 73650 0.1233% | $268,822.50 | 1 | 1 | <0.0001% |
| Kalowski Lee | Chief Financial Officer | 40953 0.0686% | $149,478.45 | 0 | 4 | |
| OCAMPO CHRISTINE | See Remarks | 21590 0.0361% | $78,803.50 | 1 | 0 | |
| Morrison Jodie Pope | President and CEO | 19551 0.0327% | $71,361.15 | 0 | 3 | |
| Buckley Stephen Jr. | director | 11000 0.0184% | $40,150.00 | 2 | 0 | |
| Little Paul Sean | CHIEF FINANCIAL OFFICER | 10000 0.0167% | $36,500.00 | 1 | 0 | <0.0001% |
| Gros David-Alexandre C | Chief Executive Officer | 9000 0.0151% | $32,850.00 | 3 | 0 | <0.0001% |
| Kuwahara Jon | See Remarks | 5974 0.01% | $21,805.10 | 0 | 2 | |
| Perrin Steven | President | 1000 0.0017% | $3,650.00 | 1 | 0 | <0.0001% |
| McBride John S. | Chief Operating Officer | 0 0% | $0 | 0 | 4 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$7,150,333 | 87 | -8.28% | $207.01M | |
$21,540,805 | 87 | 0.99% | $217.93M | |
$69,130,029 | 69 | 25.63% | $240.78M | |
$11,468,215 | 44 | 17.78% | $246.73M | |
$48,218,096 | 42 | 0.89% | $204.72M | |
$2,545,071 | 34 | 16.59% | $230.29M | |
$63,049,419 | 31 | 2.87% | $207.33M | |
$18,554,304 | 31 | -11.72% | $241.52M | |
$41,069,367 | 23 | 54.64% | $211.17M | |
$3,513,995 | 18 | -13.04% | $229.96M | |
$2,081,205 | 17 | -20.90% | $211.4M | |
Eledon Pharmaceuticals, Inc. (ELDN) | $11,230,365 | 11 | -45.81% | $218.05M |
$18,262,420 | 10 | 29.82% | $210.81M | |
$145,296,407 | 8 | -0.98% | $215.31M | |
$94,000,000 | 7 | -20.84% | $234.78M | |
$55,858,393 | 5 | 14.12% | $204.11M | |
$317,601 | 5 | -23.48% | $249.07M | |
$11,194,630 | 4 | -22.97% | $255.36M | |
$4,888,000 | 3 | -20.50% | $246.36M |
ELDN Institutional Investors: Active Positions
| Increased Positions | 64 | +336.84% | 23M | +124.77% |
| Decreased Positions | 5 | -26.32% | 3M | -16.61% |
| New Positions | 45 | New | 16M | New |
| Sold Out Positions | 3 | Sold Out | 2M | Sold Out |
| Total Postitions | 78 | +310.53% | 38M | +108.16% |
ELDN Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Bvf Inc/Il | $26,117.00 | 10.49% | 6.29M | 0 | 0% | 2024-12-31 |
| Ra Capital Management, L.P. | $14,800.00 | 5.94% | 3.57M | +4M | New | 2024-12-31 |
| Vanguard Group Inc | $12,013.00 | 4.82% | 2.89M | +1M | +84.9% | 2024-12-31 |
| Sphera Funds Management Ltd. | $10,589.00 | 4.25% | 2.55M | +1M | +96.68% | 2024-12-31 |
| First Light Asset Management, Llc | $9,664.00 | 3.88% | 2.33M | +2M | New | 2024-12-31 |
| Blue Owl Capital Holdings Lp | $8,134.00 | 3.27% | 1.96M | +2M | New | 2024-12-31 |
| Woodline Partners Lp | $6,938.00 | 2.79% | 1.67M | +828,930 | +98.34% | 2024-12-31 |
| Schonfeld Strategic Advisors Llc | $6,290.00 | 2.53% | 1.52M | +15,750 | +1.05% | 2024-12-31 |
| Ensign Peak Advisors, Inc | $5,249.00 | 2.11% | 1.26M | +821,918 | +185.53% | 2024-12-31 |
| Frazier Life Sciences Management, L.P. | $4,883.00 | 1.96% | 1.18M | +1M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.